<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432770</url>
  </required_header>
  <id_info>
    <org_study_id>1779-06-001</org_study_id>
    <nct_id>NCT00432770</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 in Healthy Volunteers</brief_title>
  <official_title>A Phase 1, Single-Site, Double-Blind,Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus or Intravenous Bolus Followed by Continuous Infusion Administration of ARC1779 Compared to Placebo in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Archemix Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Archemix Corp.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the overall safety and tolerability of ARC1779 in
      healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with
      respect to parameters of platelet function and von Willebrand Factor activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to establish the overall safety and tolerability of ARC1779 in
      healthy volunteers, and to characterize its pharmacokinetic and pharmacodynamic profile with
      respect to parameters of platelet function and von Willebrand Factor activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>42</enrollment>
  <condition>Thrombosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC1779</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 to ≤ 65 years of age

          -  Weight ≤ 110 kg

          -  Negative qualitative urine drug/alcohol test

          -  Female volunteers must be of non-childbearing potential

          -  Male volunteers must agree to use a medically acceptable contraceptive

          -  Volunteers must be capable of understanding and complying with the protocol and must
             have signed the informed consent document

        Exclusion Criteria:

        Any clinically significant medical disorder (e.g. diabetes, hypertension, etc.)

          -  Tendency to bleed easily

          -  History of recent trauma or surgery

          -  History of gout or renal stones

        Clinically significant abnormal lab parameters for the following:

          -  PT INR &gt; 1.4

          -  aPTT &gt; reference laboratory values

          -  Serum creatinine &gt; 1.3 mg/dL

          -  Platelet count of ≤ 100,000/mm3

          -  ALT/AST &gt; 2 times ULN

          -  WBC ≤ 3000 x 109/L

          -  Hemoglobin &lt; 11 g/dL

          -  Total bilirubin &gt; 1.2 mg/dL

          -  CBT &gt; 15 min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bioanalytical Systems, Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2007</study_first_posted>
  <last_update_submitted>April 19, 2007</last_update_submitted>
  <last_update_submitted_qc>April 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

